Gonorrhea – Drug Pipeline Landscape, 2022

Gonorrhea – Drug Pipeline Landscape

Gonorrhea is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. Gonorrhea most commonly affects the urethra, rectum, or throat. In women, gonorrhea can also infect the cervix. Symptoms of gonorrhea in men include painful urination, pain or swelling in a t*sticle and in women increased vaginal discharge, painful urination, vaginal bleeding between periods and abdominal or pelvic pain . The diagnosis of gonorrhea can be made after analysis of a sample of cells. Samples can be taken by urine test or by swabbing the affected area.

Treatment for gonorrhea includes a single intramuscular injection of the antibiotic ceftriaxone. Several clinical trials are currently underway to develop drugs for gonorrhea. The most promising trials are testing new antibiotics against gonorrhea bacteria. These new antibiotics are designed to be more effective against gonorrhea bacteria than existing antibiotics. Other ongoing trials are testing candidate gonorrhea vaccines. These vaccines are designed to prevent gonorrhea infections by inducing an immune response against the bacteria.

Learn more about Gonorrhea – Drug Pipeline Landscape here: https://www.globalinsightservices.com/reports/gonorrhea-drug-pipeline-landscape-2022/

Report Highlights
The Global Insight Service report, Gonorrhea – Drug Pipeline Landscape, 2022 provides an overview of drugs in the pipeline for gonorrhea. This report covers detailed information on gonorrhea drugs in development, evaluation by target, mechanism of action, route of administration and molecule type. Product portfolio by company, development stage and key regulatory designations, agreements and milestones have been presented to provide information and thus help industry players in their decision-making. The Gonorrhea Pipeline report helps in understanding the drugs that are under development in the drug development process globally.

Methodology
The research process includes extensive secondary research of public domain and other authentic sources to add or update pipeline product information. Secondary research sources include, but are not limited to, company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences and clinical trial registries.

To stay “ahead” of your competitors, request a sample: https://www.globalinsightservices.com/request-sample/GIS31043/

Scope
The pipeline landscape report provides an analysis of pipeline products based on multiple stages of development ranging from discovery to pre-registration. The report provides a review of the companies’ in-process therapeutics based on information from company and industry specific sources. The pipeline report covers the evaluation of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA), and molecule type. Full pipeline product profiles with details such as company overview, stage of development; Molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key agreements, clinical trials and major upcoming milestones are included.

Key players:

– Alopexx Pharmaceuticals Inc.
– Biolytic Pharma
– Debiopharm International SA.
– Entasis Therapeutics
– Evofem Inc
– GlaxoSmithKline
– Microbiotix Inc.

Get a Custom Scope to Meet Your Needs Ask an Expert: https://www.globalinsightservices.com/request-customization/GIS31043/

Contact us:

Global Insight Services LLC
16192 Coast Road, Lewes DE 19958
Email: [email protected]
Phone: +1-833-761-1700

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research company headquartered in Delaware, USA. We are committed to providing our clients with the highest quality data, analysis and tools to meet all of their market research needs. With GIS, you can be assured of quality deliverables, a robust and transparent research methodology, and superior service.

This press release was published on openPR.

Comments are closed.